

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on May 7, 2008.

PATENT
Attorney Docket No.: 016930-003712US
Client Reference No.: CJ01661

TOWNSEND and TOWNSEND and CREW LLP

By: /Cindy M. Keefe/
Cindy M. Keefe

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Nielsen et al.

Application No.: 10/086,294

Filed: February 28, 2002

For: COMBINED TUMOR
SUPPRESSOR GENE THERAPY AND
CHEMOTHERAPY IN THE
TREATMENT OF NEOPLASMS

Confirmation No.: 3210

Examiner: Joanne Hama

Art Unit: 1632

THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

/Nathan S. Cassell/

Nathan S. Cassell
Reg. No. 42,396

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 303-571-4000
Fax: 303-571-4321
NSC:c2k